SITESEARCH
home | sitemap | contact us
Call : (718) 732-4000  Fax : (718) 881-3035  Email : info@eastchestercenter.com
 

Clinical Studies Available 

Phase Intervention Targeted Diseases Purpose Links Status

  Phase I/II      

 CPI-613  Advcanced Cancer, Metastatic Canacer, Lymphoma, Solid Tumors, Advanced Malignancies

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients

 http://clinicaltrials.gov/ct2/show/NCT00741403 Recruiting
Phase I/II     CPI-613

Cancer

Pancreatic Cancer

Pancreatic Carcenoma

  

The objectives of this study are:

  • To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients.
  • To compare the safety and efficacy of CPI-613/Gemcitabine combination vs. Gemcitabine alone in patients with carcinoma of the pancreas
  http://clinicaltrials.gov/ct2/show/NCT00907166?intr=%22CPI-613%22&rank=1 Recruiting
Phase III
Neratinib (HKI-272)
 
Early –Stage HER- 2/neu Overexpressed/Amplified Breast Cancer
  
A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab In Women with Early –Stage HER-2 neu Overexpressed Amplified Breast Cancer.  Neratinib or Placebo Administration dosing is orally on a once-a day-schedule
 
Primary Outcome Measures:
  • disease free survival [ Time Frame: five years ] [ Designated as safety issue: No ]
     

Secondary Outcome Measures:
  • Common Terminology for Adverse Events (CTCAE) version 3 [ Time Frame: duration of subject's participation on active portion of study ] [ Designated as safety issue
  http://clinicaltrials.gov/ct2/show/NCT00878709?term=Randomized+Double-Blind+Placebo-Controlled+Trial+of+Neratinib+%28HKI-272%29&rank=1  Recruiting
Phase III Lucanix Advance Non Small Cell Lung Cancer

An International Multicenter, Randomized, Double-Blinded, Placebo Controlled Study of Lucanix (Belagenpumatucel-L).  Maintenance Therapy for Stages III/IV NSCLC who have responded to or have Stable Disease following one regimen of Front-Line, Platinum base Combination Chemotherapy

 

 http://clinicaltrials.gov/ct2/show/NCT00676507?term=Placebo+Controlled+Study+of+Lucanix&rank=1  Recruiting

 
 
Home   |   About Us   |   Our Services   |   Clinical Trials   |   Education   |   Your Visit   |   News   |   Events   |   Sitemap   |   Contact Us
Privacy Policy    |   Disclaimer © 2006 EASTCHESTER CENTER FOR CANCER CARE